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Abstract
The BCR-ABL tyrosine kinase is the defining feature of chronic myeloid leukemia (CML) and its kinase activity is required for
induction of this disease. Current thinking holds that BCR-ABL forms a multi-protein complex that incorporates several
substrates and adaptor proteins and is stabilized by multiple direct and indirect interactions. Signaling output from this
highly redundant network leads to cellular transformation. Proteins known to be associated with BCR-ABL in this complex
include: GRB2, c-CBL, p62
DOK, and CRKL. These proteins in turn, link BCR-ABL to various signaling pathways indicated in
cellular transformation. In this study we show that a triple mutant of BCR-ABL with mutations of the direct binding sites for
GRB2, CBL, p62
DOK and CRKL, is defective for transformation of primary hematopoietic cells in vitro and in a murine CML
model, while it retains the capacity to induce IL-3 independence in 32D cells. Compared to BCR-ABL, the triple mutant’s
ability to activate the MAP kinase and PI3-kinase pathways is severely compromised, while STAT5 phosphorylation is
maintained, suggesting that the former are crucial for the transformation of primary cells, but dispensable for
transformation of factor dependent cell lines. Our data suggest that inhibition of BCR-ABL-induced leukemia by disrupting
protein interactions could be possible, but would require blocking of multiple sites.
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Introduction
The BCR-ABL tyrosine kinase is the molecular hallmark of
chronic myeloid leukemia (CML) and its kinase activity is required
for disease induction [1,2]. BCR-ABL transforms Rat-1fibroblasts
[3] and B-cell precursors [4] in vitro and confers interleukin-3 (IL-3)
independent growth when expressed in IL-3 dependent myeloid
cell lines [5]. In murine bone marrow transplantation/transduc-
tion experiments, BCR-ABL infected bone marrow transplanted
into mice induces a myeloproliferative syndrome that is trans-
plantable into secondary recipients [6,7,8]. Since the tyrosine
kinase activity of BCR-ABL is essential for its oncogenic activity in
vitro and in vivo [1,2], much effort has been directed at determining
which of its substrates are required for leukemogenesis. A number
of BCR-ABL substrates have been identified, including BCR-ABL
itself, CBL, CRKL, the p85 kDa regulatory subunit of phospho-
inositide (PI) 3-kinase, p62
DOK, RAS-GAP, paxillin, and SHC [9].
Co-immunoprecipitation experiments have shown that BCR-ABL
forms stable complexes with several of these substrates including
CRKL, SHC, CBL, p62
DOK, and PI3-kinase [9,10,11,12]. In
addition, tyrosine phosphorylation of BCR-ABL at specific
residues regulates the binding of proteins such as GRB2 [13]. As
a result of these interactions many intracellular signaling pathways
are activated, including the RAS, AKT and STAT pathways
[9,10,11,12]. In the complicated network of interactions that
results, the role and relative importance of individual components
has been difficult to establish.
To determine the necessity of various proteins for BCR-ABL
function, a common approach has been to identify a binding site
for a specific protein on BCR-ABL, mutate the site and analyze
the effect on BCR-ABL function. The ability of BCR-ABL
constructs to transform IL-3 dependent hematopoietic cell lines to
factor independent growth is a common tool used to assess BCR-
ABL function. For example, tyrosine 177 of BCR-ABL is the
binding site for the adaptor protein GRB2, which links BCR-ABL
to the RAS pathway [13,14]. BCR-ABL containing a mutation of
this tyrosine to phenylalanine (Y177F) is still able to transform
myeloid cell lines to IL-3 independent growth [15]. This Y177F
mutant is also capable of inducing leukemia in a murine leukemia
model, but the phenotype of the leukemia is lymphoid as opposed
to myeloid [16]. Similar results were seen with a mutant lacking
the SH2 domain. This BCR-ABL SH2 domain deletion mutant
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induces a lymphoid leukemia or a CML-like disease in mice, but
the disease latency is increased as compared to full length BCR-
ABL [20]. The SH2 domain is reported to mediate direct binding
of BCR-ABL to CBL [21,22] and p62
DOK [23]. In the C-terminus
of BCR-ABL, a proline-rich region is a direct binding site for the
adaptor protein CRKL. Deletion mutants in this region are
capable of rendering myeloid cells growth factor independent in
the background of p210
BCR-ABL [24], and are also capable of
inducing leukemia in mice in the p185
BCR-ABL background [25].
Although mutation of individual domains abolishes the direct
interactions of a signaling protein with BCR-ABL, indirect
interactions confound the ability to determine the role of a
specific protein or pathway in BCR-ABL transformation. For
example, direct binding of CRKL to BCR-ABL is abolished in the
proline-rich deletion mutant, but CRKL interacts indirectly with
BCR-ABL and is still tyrosine phosphorylated [24]. Therefore, to
address the role of various signaling pathways simultaneously and
to circumvent difficulties posed by the potential for indirect
interactions, we created a mutant of BCR-ABL with a tyrosine to
phenylalanine mutation at amino acid 177 (Y177F), an SH2
domain deletion (DSH2) and a deletion of the C-terminal proline-
rich region (DPro). We assessed the ability of this triple mutant to
transform myeloid cell lines and induce leukemia and analyzed its
ability to interact with signaling proteins and activate downstream
signaling pathways.
Results
The triple mutant of BCR-ABL is capable of inducing
growth factor independence
32D cell lines were generated containing the pSRa vector, full
length BCR-ABL without mutations, herein referred to as wild
type BCR-ABL (WT), mutants of BCR-ABL containing a tyrosine
to phenylalanine mutation at amino acid 177 (Y177F), a deletion
of the SH2 domain (DSH2), a deletion of a C-terminal proline-rich
region (DPro) and a triple mutant of BCR-ABL (triple) containing
all three. These are reported to be direct binding sites for GRB2
(Y177)[13,14], CBL[21,22] and p62
DOK (SH2 domain)[23], and
CRKL (proline-rich region)[24]. Individual clones were isolated
from soft agar cultures and evaluated for expression of BCR-ABL.
Several clones expressing BCR-ABL at comparable levels were
selected and analyzed for IL-3 dependence by cell proliferation
and viability assays. All clones were maintained in the presence of
IL-3 prior to assessment of factor independent growth. The
parental 32D cells were unable to proliferate in the absence of IL-
3, whereas wild type BCR-ABL, the Y177F, DSH2, DPro and the
triple mutant BCR-ABL grew at comparable rates, indicating the
triple mutant is capable of inducing factor independent growth.
The result of a representative cell proliferation assay with the triple
mutant is shown in Figure 1A (data not shown for single mutants).
The wild type and triple mutant clones represented in Figure 1
were chosen for further study due to similarity in BCR-ABL
expression levels. Growth curve measurements for additional wild
type and triple mutant clones (Figure S1) were carried out to
confirm that the observed phenotypes were not attributable to
random mutational events. Assays of proliferation and viability as
determined by trypan blue dye exclusion, performed in the
presence and absence of IL-3, yielded similar results, with the
triple mutant proliferating and remaining viable at levels
comparable to wild type and single mutants in the absence of
IL-3 (data not shown). Expression levels of BCR-ABL and a triple
mutant clone are shown in Figure 1B.
Kinase Assays
It has previously been shown that individual mutations of the
Tyr 177 to Phe, and deletion of the SH2 and Proline domains of
BCR-ABL do not abolish the associations between BCR-ABL and
its substrates [17,22,23,24,26], nor do they completely abolish the
kinase activity [19,20,25,27]. Kinase assays were performed to
determine if the kinase activity of BCR-ABL was impaired in the
triple mutant. Results, shown in Figure 2, demonstrate the kinase
activity of the BCR-ABL triple mutant is 40-50% lower than that
of wild type, similar to that of the BCR-ABL mutant lacking only
the SH2 domain. The kinase activity of the single mutants has
been reported previously by various groups. Cortez et al.
investigated the Y177F and SH2 mutants and found they both
were able to transphosphorylate an ABL kinase substrate at similar
levels to wild type [28]. Ilaria and Roumianstev both saw a
decrease in the kinase activity of a DSH2 mutant compared to wild
type BCR-ABL using phospho-tyrosine immunoblots [19,20]. Dai
[25] and Senechal [27] examined the DPro mutation in the p185
and p210 backgrounds, respectively, and also demonstrated that
the kinase activity was still present in these mutant forms of BCR-
ABL. Since, as reported by these groups, mutation of these
Figure 1. The triple mutant of BCR-ABL is capable of inducing
growth factor independence. 32D cell lines matched for BCR-ABL
expression were analyzed for their requirement of interleukin-3 (IL-3) for
growth. (A) Representative graph of cell proliferation assay on 32D cell
lines matched for expression of BCR-ABL grown in the absence of IL-3.
(B) Western blot of BCR-ABL (upper panel) and ABL (lower panel)
showing relative expression levels of cell lines shown in A.
doi:10.1371/journal.pone.0007439.g001
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with its substrates, nor its ability to induce leukemia in mice, we
focused our investigation on the triple mutant encompassing each
of these component mutants in our studies.
Protein-protein interactions with BCR-ABL wild type and
triple mutant
To further analyze the biochemical properties of cell lines
expressing the triple mutant, whole cell lysates from independent
clones were analyzed by immunoprecipitation and immunoblot-
ting. These studies demonstrated that the associations between
BCR-ABL and GRB2, p62
DOK and c-CBL, were strongly
reduced, but not completely eliminated in the triple mutant
(Figure 3A, B and C). Surprisingly, the amount of CRKL
interacting with the triple mutant remained comparable to that of
the wild type clones (Figure 3D), which is similar to previous
results with the DPro mutant alone [24].
Tyrosine phosphorylation of BCR-ABL substrates
The level of tyrosine phosphorylation of BCR-ABL, c-CBL,
CRKL, p62
DOK and STAT5 were assessed next. Tyrosine
phosphorylation levels from three different experiments were
quantitated and normalized for total levels of the specific protein
being analyzed. The phosphorylation levels relative to wild type
(defined as 100%) are shown in Figure 4 along with representative
immunoblots. As shown in Figure 4A, the relative level of BCR-
ABL tyrosine phosphorylation is reduced by approximately two-
fold in the triple mutant as compared to wild type (p=0.007),
consistent with the reduced kinase activity. Similarly, CBL, which
is a component of the BCR-ABL signaling complex, and CRKL,
which is directly associated with and phosphorylated by BCR-
ABL, are approximately four-fold (Figure 4B; p=0.003) and two-
fold (Figure 4C; p=0.034) less efficiently tyrosine phosphorylated
in the context of the triple mutant as compared to wild type BCR-
ABL, consistent with reduced BCR-ABL kinase activity and
partial disruption of key docking elements within the triple mutant
critical to efficient assembly of the BCR-ABL signaling complex.
In contrast, the relative tyrosine phosphorylation levels of the
downstream BCR-ABL targets p62
DOK (Figure 4D; p=0.81) and
STAT5 (Figure 4E; p=0.38), are unchanged in the setting of triple
mutant BCR-ABL. Wild type BCR-ABL and the triple mutant are
equally sensitive to imatinib, as evidenced by complete suppression
of tyrosine phosphorylation upon treatment with 10 mM imatinib.
In both cases, tyrosine phosphorylation of all examined down-
stream targets is also abrogated.
Activation state of signaling pathways
The activation state of various signaling proteins activated by
BCR-ABL (STAT5, MAPK, MEK and AKT) was analyzed in
whole cell lysates from cells expressing wild type BCR-ABL and
the triple mutant, using phosphospecific antibodies (Figure 5). As
with the data presented in Figure 4, the level of phosphorylation
from three different experiments was quantitated and normalized
for expression of the specific protein being analyzed. The
phosphorylation levels relative to wild type (defined as 100%)
are shown. The relative level of STAT5 tyrosine phosphorylation
was slightly reduced in the triple mutant as compared to wild type,
but did not reach statistical significance (Figure 5A; p=0.061),
consistent with findings described above (Figure 4E). In contrast,
statistically significant reductions in the relative levels of phospho-
MAPK (Figure 5B; ,four-fold; p=0.003), phospho-MEK
(Figure 5C; ,two-fold; p=0.004), and phospho-AKT (Figure 5D;
,five-fold; p=0.001) were evident in the setting of the BCR-ABL
triple mutant.
The level of STAT5 phosphorylation was also analyzed in
primary bone marrow cells infected with matched retroviral stocks
for the triple mutant, wild type BCR-ABL or vector control. GFP
positive cells were isolated from each of the infected cell groups
and the level of STAT5 phosphorylation measured by flow
cytometry and western blotting (Figure 6). Similar to the results
seen in the cell lines (Figures 4E and 5A), the levels of phospho-
STAT5 in bone marrow infected with the triple mutant is
comparable to that seen in wild type relative to the vector only
control (Figure 6A,B).
The BCR-ABL triple mutant fails to induce the outgrowth
of B-lymphoid cells and myeloid cells
The ability of the BCR-ABL triple mutant to transform primary
B-lymphoid cells was assessed in Whitlock-Witte cultures. In these
assays, cells were plated in serial dilutions, from 1610
3 cells per
well to 1610
5 cells per well. The wells were assessed daily for
outgrowth, with wells containing at least 1610
6 non-adherent cells
scored as positive. As shown in Figure 7A, wild type BCR-ABL
induced outgrowth at all but the lowest dilution (yellow line). In
contrast the triple mutant was unable to induce the outgrowth of
B-lymphoid cells at any dilution plated (Figure 7B), similar to the
results seen with the MIG vector control (Figure 7C).
The triple mutant was also assessed for transformation ability in
myeloid colony forming assays. Normal bone marrow requires the
addition of cytokines to support colony formation in semisolid
media, while expression of BCR-ABL abrogates this requirement
[4]. In methylcellulose cultures of murine bone marrow infected
with BCR-ABL and supplemented with IL-3, IL-6 and SCF, there
was no statistically significant difference between the ability of the
triple mutant and wild type to form colonies (Figure 7D). However
in the absence of cytokines, the triple mutant yielded only 4% of
the colonies formed in the wild type cultures (Figure 7E). To
determine whether the colonies growing under the various
conditions contained the BCR-ABL construct, individual colonies
were analyzed for GFP by PCR. In the presence of growth factors,
Figure 2. Kinase activity of triple mutant BCR-ABL is 40–50%
that of wild type. 32D cells normalized for BCR-ABL expression were
immunoprecipitated and kinase activity was assayed using a peptide
substrate containing the consensus ABL kinase binding site. Assays
were performed in triplicate for each cell line: wild type (WT), DSH2 and
triple mutant.
doi:10.1371/journal.pone.0007439.g002
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expressed GFP compared to 100% of wild type colonies. Though
only 4 colonies were present in the triple mutant cultures without
growth factors, all expressed GFP (data not shown). Thus, the
triple mutant appears to have a profound defect in its ability to
transform primary cells as measured in these assays.
The BCR-ABL triple mutant fails to induce leukemia in
mice
To assess the ability of the triple mutant to induce a
myeloproliferative disease in vivo, lethally irradiated Balb/c mice
were transplanted with bone marrow transduced with wild type,
triple mutant or empty vector. Assays were carried out using
retroviral supernatants of MIG-wild type, the MIG-triple mutant
and MIG vector only, matched for GFP expression. As shown in
Figure 8A, the triple mutant failed to induce leukemia. Four of 5
mice transplanted with bone marrow infected with the triple
mutant vector survived up to 294 days post transplant when they
were sacrificed for pathological examination of tissues. A fifth
mouse was sacrificed after 118 days for pathological examination
to look for evidence of disease. For comparison, mice transplanted
with wild type virus had a post-transplant survival of between 20–
24 days (Figure 8A). Peripheral blood counts from mice
transplanted with the triple mutant and vector only were in the
normal range (Table 1). The tissues harvested from the triple
mutant mice showed no obvious morphological abnormalities
(Figure 8C; b, e, h), and were similar to the vector only control
animals (Figure 8C; a, d, g). In contrast the wild type mice
exhibited massive expansion of leukemic cells in the liver, spleen
and peripheral blood (Figure 8C; c, f, i). Southern blots were
performed using genomic DNA from the spleens and bone
marrow of the transplanted mice to analyze for integration of viral
DNA, using the IRES from the MIG vector as a probe. Proviral
integration was only seen in the wild type mice and in the bone
marrow of one of the vector only mice (data not shown). As the
sensitivity of Southern blot analysis is relatively low, PCR was
performed to amplify GFP from RNA isolated from the spleen of
each mouse, to ensure that there was expression of the retroviral
constructs in each animal. As shown in Figure 8B, all the mice
transplanted with the triple mutant expressed the retroviral vector,
suggesting the presence of a small population of cells transduced
with the retroviral construct was present, but failed to expand.
Discussion
The BCR-ABL protein is known to associate with and activate
numerous cellular signaling proteins. The emerging view is that
BCR-ABL assembles a multi-protein complex whose signaling
output leads to cellular transformation. Deciphering the contri-
bution to transformation of individual domains of BCR-ABL or
signaling proteins has been problematic as many proteins can
interact both directly and indirectly with BCR-ABL. For example,
deletion of a proline-rich motif in the C-terminus of BCR-ABL
abolishes direct binding of BCR-ABL to the N-terminal SH3
domain of CRKL; however, CRKL remains tyrosine phosphor-
ylated and associated with BCR-ABL in cells expressing this
deletion mutant [24]. This is likely the result of interactions
between CRKL and other adaptor or signaling molecules, such as
c-CBL or p62
DOK which have been shown to link CRKL
indirectly to BCR-ABL [22,23]. In addition, an individual domain
or binding site can mediate binding to more than one protein. For
example, the SH2 domain mediates an association of BCR-ABL
with CBL [21,22] and p62
DOK [23]. Even the use of animals that
lack specific signaling proteins has not been particularly revealing.
In some cases, such as GRB2, the null phenotype is embryonic
lethal [29]. In others, such as c-CBL null animals, no defect in
BCR-ABL transformation has been observed [30]. This result
could be interpreted as a lack of necessity of the specific protein for
BCR-ABL function or compensation for the deleted gene by other
proteins.
To investigate the necessity of various signaling proteins for
BCR-ABL, we sought to identify a BCR-ABL mutant that
remained kinase active, yet lacked transformation capacity. This
was accomplished by the construction of a triple mutant including
Figure 3. Interaction of BCR-ABL with various adaptor proteins is reduced, but not eliminated in the triple mutant. Lysates from the
BCR-ABL expressing 32D cell lines, control line K562 and parental 32D cells were immunoprecipitated (IP) for the indicated proteins and blotted to
determine interactions between BCR-ABL and (A) GRB2; (B) p62
DOK; (C) CBL; and (D) CRKL. Lower panels show normalization for levels of
immunoprecipitated proteins: (A and B) BCR-ABL, (C) CBL and (D) CRKL. In (D), the increased amount of BCR-ABL in the triple mutant lane on the left
compared to the outermost lane reflects the correspondingly greater amount of immunoprecipitated CRKL in this lane.
doi:10.1371/journal.pone.0007439.g003
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C-terminal proline-rich domains of ABL. In isolation the Y177F,
DSH2 and DPro single mutants of BCR-ABL are capable of
rendering myeloid cells IL-3 independent for growth, but they are
much less potent than wild type BCR-ABL for transformation of
fibroblasts. In a murine bone marrow transplantation model both
the Y177F and DSH2 mutants induced leukemia in vivo, however
in contrast to the myeloid phenotype of the wild type mice the
phenotype of these single mutants was lymphoid and latency was
increased [16,20]. The C-terminal proline-rich domain has been
examined in the p185
BCR-ABL background as a single mutation
and in combination with deletion of the ABL SH3 domain.
Mutants expressing a deletion of the proline-rich domain alone
and in combination with the SH3 domain were also capable of
transforming hematopoietic cells to factor independent growth.
The single mutations induced a leukemia similar to wild type when
transplanted into mice, however the double mutant induced an
undetermined disease with recipients surviving twice as long as
wild type recipient mice [25].
Using a triple mutant of BCR-ABL (Y177F, DSH2, and DPro),
we show that this mutant still confers growth factor independence
to 32D cells (Figure 1), but exhibits a profound defect in the
transformation of primary hematopoietic cells. To this end, we
show that in Whitlock-Witte B-cell transformation assays the
ability of the triple mutant to induce outgrowth is completely
abrogated. Furthermore, the ability to form myeloid colonies in
the absence of cytokines is severely compromised relative to wild
type (Figure 7). Consistent with these observations, the triple
mutant was found to be incapable of inducing leukemia in vivo in a
bone marrow transduction/transplantation model (Figure 8).
Thus, the mutant described here represents the first report of a
BCR-ABL mutant retaining kinase activity that is completely
transformation deficient in vivo. In vitro kinase assays revealed that
the kinase activity of the triple mutant, although reduced
compared to wild type, is equal to the activity of the DSH2 single
mutant (Figure 2). As the DSH2 mutant retains transformation
competency in both cell lines and primary cells [17,19,20], this
strongly suggests that the reduced kinase activity is not causing the
transformation defect.
Figure 4. Phosphorylation of various BCR-ABL substrates in
wild type and triple mutant BCR-ABL expressing cell lines.
Phosphotyrosine levels were determined by immunoprecipitating the
indicated proteins from BCR-ABL expressing 32D cell lines and
immunoblotting with an anti-phosphotyrosine antibody. The levels of
phosphorylation were normalized for the levels of the immunoprecip-
itated protein, and phosphorylation is reported relative to wild type
(right panel). (A) BCR-ABL; (B) CBL; (C) CRKL; (D) p62
DOK; (E) STAT5.
Treatment with 10uM imatinib inhibited phosphorylation of all
substrates examined. Data represents three separate experiments, with
a representative blot for each shown in the left panels.
doi:10.1371/journal.pone.0007439.g004
Figure 5. Activation state of various signaling pathways, in the
triple mutant BCR-ABL expressing cells, relative to wild type.
32D cell lines expressing either wild type or triple mutant BCR-ABL were
lysed and the activation state of the indicated signaling pathways was
detected by immunoblotting whole cell lysates with phosphospecific
antibodies for each pathway. (A) phospho-STAT5; (B) phospho-MAPK;
(C) phospho-MEK; (D) phospho-AKT. The levels of phosphorylation were
normalized for the whole cell levels of the protein shown in the lower
panel of each immunoblot. (A) STAT5; (B) MAPK; (C) MEK; (D) AKT.
Phosphorylation levels are reported relative to wild type (upper panels).
Data represents three independent experiments with a representative
blot shown.
doi:10.1371/journal.pone.0007439.g005
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32D cells showed that only STAT5 activation was maintained at
wild type levels, suggesting that activation of STAT5 may be
sufficient to induce IL-3 independence (Figure 5). This is consistent
with a report by Onishi and colleagues, that a constitutively active
STAT5 mutant is capable of inducing IL-3 independent growth
[31]. In contrast, the significantly reduced activity of the MAP
kinase and PI3-kinase/AKT pathways suggest that they are not
required for BCR-ABL to induce growth factor independence in
the triple mutant cell lines. This is consistent with the findings of
Cortez et al, that RAS activation alone is not sufficient for
transformation by BCR-ABL [28]. In addition to STAT5 we
found that tyrosine phosphorylation of p62
DOK is maintained in
the triple mutant (Figure 4), in contrast to CBL and CRKL
tyrosine phosphorylation. Thus it is possible that p62
DOK
phosphorylation in addition to STAT5 is required for factor-
independent growth. Many groups have attempted to determine
the role of phosphorylated p62
DOK in cellular signaling and
suggest that phosphorylated p62
DOK plays a role in the negative
regulation of growth factor stimulated pathways and/or RAS
signaling [32]. Our data suggest that CBL and CRKL phosphor-
ylation are primarily required for modulation of cellular functions
other than factor independent proliferation and survival. For
example, signaling through CRKL could affect adhesion and
migration via interactions with paxillin, CAS and CBL and by
forming complexes with focal adhesion kinases [33]. It has also
been suggested that CRKL may play a role in signaling via its
interactions with integrins, B- and T-cell receptors and various
cytokines [34]. CRKL and CBL have been shown to interact in a
multi-protein complex along with PI3-kinase when phosphorylat-
ed in BCR-ABL expressing cells [21]. Additionally, phosphory-
lated CRKL can transform fibroblasts through association with
SOS and C3G, thereby activating the RAS pathway, analogous to
the role of GRB2 in the activation of the same pathway [27]. The
pattern of tyrosine phosphorylation in the BCR-ABL triple mutant
points out the complexity of BCR-ABL signaling. We have shown
that CRKL co-immunoprecipitates with the DPro mutant of
BCR-ABL in cellular lysates, although this mutant is not capable
of directly binding CRKL [24], and suggested that this interaction
may be mediated by an association between CRKL and CBL,
which in turn binds to the ABL SH2 domain in a tyrosine
dependent manner. However, in the triple mutant, CRKL
tyrosine phosphorylation and the association of CRKL and
BCR-ABL are maintained, although the interaction between
BCR-ABL and CBL is significantly reduced (Figure 3). As we
Figure 6. Analysis of phospho-STAT5 in primary cells. GFP
positive primary bone marrow transduced with retroviral supernatants
from wild type, triple mutant BCR-ABL or vector only was analyzed for
the levels of STAT5 phosphorylation by (A) FACS analysis of cells gated
for GFP positivity and stained with phospho-STAT5-Alexa 647 antibody
or by (B) Western analysis with the indicated antibodies.
doi:10.1371/journal.pone.0007439.g006
Figure 7. BCR-ABL triple mutant fails to induce the outgrowth
of progenitor B-lymphoid cells and myeloid progenitor cells.
Transformation of primary B-lymphoid progenitors was assessed in
Whitlock/Witte cultures with bone marrow incubated with retroviral
supernatants from (A) wild type; (B) triple mutant; and (C) vector only.
Cells are plated in serial dilutions from 1610
5 (black line), 3610
4 (blue
line), 1610
4 (red line), 3610
3 (green line), 1610
3 (yellow line), along
with 1610
6 non-transduced bone marrow cells. Cultures are scored
positive for growth when the number of non-adherent cells exceeded
10
6 per mL of culture medium. Myeloid transformation potential in the
presence (D) or absence (E) of cytokines was measured using colony-
forming assays of bone marrow transduced with retroviral supernatants
from wild type, triple mutant or vector only. were identical in two
separate assays.
doi:10.1371/journal.pone.0007439.g007
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CRKL in the DPro mutant, this suggests that an unidentified
protein(s) mediates the indirect interaction between CRKL and
BCR-ABL.
Despite activation of STAT5, the BCR-ABL triple mutant is not
able to induce leukemia in vivo. As noted, several signaling
pathways are significantly impaired in this mutant, including the
MAPK and PI3-kinase/AKT pathways (Figure 5). The fact that
the respective single mutants are leukemogenic suggests that the
combination of all three mutations abolishes leukemogenicity by
overcoming the redundancy of the system. For example, the BCR-
ABL Y177F mutant is deficient in GRB2 binding, but still
activates RAS in 32D and BaF3 cells, likely via SH2 domain
dependent interaction with GRB2 and SHC [15]. The fact that
RAS activation via the SH2 domain is preserved in the Y177F
mutant could explain why this mutant still maintains leukemoge-
nicity in vivo. In addition, the SH2 domain of BCR-ABL has been
shown to be required for activation of AKT through its association
with the p85 subunit of PI3-kinase [35]. The combined
impairment of PI3-kinase and RAS activation may explain the
triple mutant’s inability to transform primary hematopoietic
progenitor cells.
It is not entirely clear which precise functional defect is
responsible for the loss of leukemogenic potential. Bone marrow
containing similar percentages of GFP positive cells (Table S1) of
vector control, wild type or triple mutant were used for
transplantation. Proviral integration in hematopoietic tissues from
mice transplanted with bone marrow infected with the triple
mutant was detected by PCR (Figure 8B), but not Southern
blotting, indicating that only a small fraction of hematopoietic cells
contained the triple mutant construct. Our results suggest that
hematopoietic cells transduced with the triple mutant are at a
selective disadvantage compared to cells transduced with wild type
BCR-ABL or empty vector, as their proportion was reduced after
engraftment. Further experiments will be required to determine
whether this reflects failure of the cells to engraft or failure to
expand after engraftment. The data from the B-cell and myeloid
colony assays are clearly much more compatible with the second
possibility. The data from the primary hematopoietic cells also
support this assertion. Given the evidence demonstrating expres-
sion of BCR-ABL and of comparable levels of downstream
signaling in primary cells (Figure 6), the identical nature of the
vector backbone in all three constructs used and the fact that cell
lines with high expression of the triple mutant were easily derived,
low expression of the triple mutant does not appear to be a
plausible explanation for the lack of disease in the mice transduced
with the triple mutant bone marrow.
In summary, we show that mutation of BCR-ABL tyrosine 177
to phenylalanine in combination with deletion of the SH2 and
proline rich domains abolishes the capacity of BCR-ABL to
Figure 8. BCR-ABL triple mutant fails to induce leukemia in
mice. Murine bone marrow transplantation studies were performed,
transplanting bone marrow infected with retroviral supernatant from
MIG-BCR-ABL-wild type, MIG- BCR-ABL-triple mutant or MIG vector
alone, into lethally irradiated recipients. Mice were monitored post
transplant for signs of disease onset. (A) Survival curves for the three
recipient populations. (B) Green fluorescent protein (GFP, upper panel)
or glyceraldehyde-3-phosphate dehydrogenase (GAPDH, lower panel)
was amplified by RT-PCR from RNA purified from spleens of triple
mutant, wild type or vector only recipients and visualized on agarose
gels. (C) H&E stain from the liver (a–c), spleen (d–f) and Wright/Giemsa
stain from peripheral blood smear (g–i) of representative mice at
harvest; vector only (upper panels), triple mutant (center panels) and
wild type (lower panels).
doi:10.1371/journal.pone.0007439.g008
Table 1. Clinical characteristics of mice transplanted with MIG vector, MIG-WT and MIG-triple mutant.
BCR-ABL construct Disease WBC (x106/L) Lym (x106/L) Mon (x106/L) Gra (x106/L) Liver (g) Spleen (g)
WT (n=6) CML-like 201669 20.765.8 6.6362.95 174666 2.6260.28 0.8260.13
Triple (n=5) Normal 12.862.4 6.3261.09 0.9660.26 5.5261.26 1.1460.07 0.1060.01
MIG vector (n=6) Normal 1563.6 7.7362.5 1.4760.27 5.861.14 0.9260.12 0.0960.02
See text for details. Pre-moribund mice transplanted with MIG vector, MIG-wild type and MIG-triple were sacrificed for pathological evaluation. Counts of total white
blood cells (WBC), lymphocytes (Lym), monocytes (Mon) and granulocytes (Gra) were analyzed from peripheral blood on a VetABC blood analyzer. Livers and spleens
were harvested, weighed and analyzed histologically.
doi:10.1371/journal.pone.0007439.t001
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capable of inducing factor-independent growth in cell lines. This
implies that a combination of small molecules that simultaneously
block Y177 [36], the protein binding SH2 domain and the proline
rich region could suppress BCR-ABL induced leukemia despite




Constructs containing the point mutation of tyrosine 177 to
phenylalanine (Y177F) [13], deletion of the ABL SH2 domain
(DSH2) [17], and deletion of the proline-rich region of the C
terminus (DPro) [24], have been described previously. A ‘‘triple
mutant’’ construct containing all three changes was created from
wild-type BCR-ABL by a series of standard subcloning steps in a
modified pGEM5z vector (Promega, Madison, WI, USA). We
recognize that since BCR-ABL is a fusion protein that is not
naturally occurring, the term ‘‘wild type’’ is technically incorrect.
However, cumbersome terminology such as ‘‘BCR-ABL with no
mutations in the coding sequences of BCR and ABL’’ would be
required to accurately describe the starting clone. For this reason,
we have chosen to use the term wild type to describe the fusion
protein that is observed in patients with CML. The wild type,
Y177F, DSH2, DPro and triple mutant forms of BCR-ABL were
excised from the modified pGEM5z vector as EcoR1 cassettes and
subcloned into the pSRa-MSV-tk-neo retroviral expression vector
(pSRa) [37], yielding plasmids pSRa-p210-wild type (WT), pSRa-
p210-Y177F (Y177F), pSRa-p210-DSH2 (DSH2), pSRa-p210-
DPro (DPro) and pSRa-triple mutant (triple) for expression in
32Dcl3 cells. Constructs were also subcloned into the MSCV-
IRES-GFP (MIGR1) [2], yielding plasmids MIG-p210 wild type
(WT) and MIG-triple mutant (triple) for use in B-cell lymphoid
outgrowth assays, colony forming assays and murine bone marrow
transplantation experiments.
Cells and cell culture
The 32Dcl3 cell line (herein referred to as 32D cells) was
obtained from Joel Greenberger, University of Massachusetts
Medical Center, Worcester, MA [38]. 32D cell lines expressing
wild type, Y177F, DSH2, DPro and the triple were generated by
electroporation or by infection with retroviral supernatant
generated from 293T cells [39]. Mass cultures were expanded in
RPMI-1640 supplemented with 10% fetal bovine serum (FBS) and
15% WEHI-3B conditioned media as a source of murine
interleukin-3 (IL-3). Individual clones were isolated by plating
cells in 0.25% soft agar (Seakem, FMC Bioproducts, USA) in
complete media containing 15% WEHI-3B conditioned media.
Individual colonies were picked after 10–14 days and expanded in
RPMI-1640 supplemented with 10% FBS and 15% WEHI-3B
conditioned media. With IL-3 in the media, selection for growth
factor independence was avoided. Individual clones were analyzed
for BCR-ABL expression by immunoblot analysis. K562 cells, a
BCR-ABL positive cell line [40], were cultured in RPMI-1640
supplemented with 10% FBS. Imatinib, kindly provided by E.
Buchdunger (Novartis, Basel, Switzerland) was prepared freshly as
a 10 mM stock solution in sterile phosphate-buffered saline (PBS)
and diluted in RPMI 1640 medium immediately prior to use.
Cell proliferation and viability assays
Factor independent growth was assessed with a tetrazolium
compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphe-
nyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) (Promega,
Madison, WI, USA) assays as described [41]. Briefly, 1610
4 cells
were plated in quadruplicate wells of four separate 96 well plates,
with and without IL-3. MTS was added to one plate, which was
incubated at 37uC for 4 hours, followed by measurement of the
optical density (OD) at 490 nm. This was repeated at 24 hour
intervals with the remaining three plates. For cell viability assays,
2610
6 cells were cultured in T25 flasks, with and without IL-3.
Viable cells that excluded trypan blue were counted daily for 7
days.
Kinase assays
Immunoprecipitated wild type, DSH2, and triple mutant BCR-
ABL proteins from the 32D cell lines were used to measure the
relative kinase activity of the proteins. Kinase activity was assayed
using a synthetic NH2-terminal biotin linked peptide substrate
containing the consensus binding sequence for the ABL kinase
(biotin-EAIYAAPFAKKK-amide; New England Peptide, Gard-
ner, MA, USA) [42,43]. Briefly, 32D cell lysates normalized for
BCR-ABL expression were immunoprecipitated using the ABL
antibody (K12, Santa Cruz Biotechnologies, Santa Cruz, CA,
USA) followed by incubation with protein-A-sepharose. Immuno-
precipitates were washed extensively in kinase buffer (25 mM Tris-
HCl, pH 7.5, 5 mM b-glycerophosphate, 2 mM DTT, 0.1 mM
sodium orthovanadate [Na3VO4], 10 mM MgCl2) and resus-
pended in the same. Kinase assays were incubated at 30uC for 10
minutes in kinase buffer plus 50 uM ATP, [c
32P]ATP at 5000–
5000 cpm/pmol and 2 uM peptide substrate. Assays were
terminated with guanidine hydrochloride. A portion of the assay
was spotted onto streptavidin coated membranes (SAM
2H,
Promega, Madison, WI), washed and dried as recommended by
the manufacturer. Phosphate incorporation was detected by liquid
scintillation counting. Assays were performed in triplicate for each
BCR-ABL protein, with and without imatinib in the assay to
control for kinase activity due to other kinases aside from BCR-
ABL that might be present in the immunoprecipitates. Back-
ground binding was corrected using reactions containing no
peptide. Counts were averaged in each assay, corrected for
background counts and for BCR-ABL expression, as determined
by Western blotting. Three replicate assays were performed and
the activity relative to p210 wt was calculated.
Immunoprecipitations and immunoblotting
Cells were lysed in NP40 lysis buffer (20 mM Tris, pH 8.0,
1 mM EDTA, 150 mM NaCl, 1% NP40, 10% glycerol, also
containing 10 ug/mL aprotinin, 1 mM Na3VO4 and 1 mM
phenylmethylsulfonyl fluoride). Equal amounts of whole cell lysate
were run on SDS-PAGE gels and transferred to PVDF
membranes (Immobilon-P, Millipore, Temecula, CA, USA) for
4 hours at 0.55 amps in 25 mM Tris, 192.5 mM glycine and 20%
methanol. Non-specific binding sites were blocked with either
2.5% gelatin (for anti-phosphotyrosine blots) or 5% non-fat milk in
TBS-T (10 mM Tris, pH 8.0, 150 mM NaCl, 0.05% Tween20)
for 1 h at 25uC. The blots were incubated at room temperature
with anti-phosphotyrosine antibodies (4G10), from Millipore, or
one of the following antibodies from Cell Signaling (Beverly, MA,
USA): phospho-AKT (S473), phospho-MAPK (T202/Y204),
phospho-STAT5 (Y694) or phospho-MEK (S217/221). Blots
were stripped and reprobed with antibodies recognizing AKT,
MAPK, STAT5 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and MEK (Cell Signaling), respectively. Antibody reactions
were detected by enhanced chemiluminescence (Pierce, Rockford,
IL, USA) and quantitated using the Lumi Analyst software
(Boehringer Mannheim, Roche Diagnostics, Indianapolis, IN,
USA). For immunoprecipitation studies, equal amounts of lysate
were incubated with antibody followed by incubation with either
BCR-ABL Triple Mutant Function
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tations were: c-CBL (C-15), c-ABL (K12), CRKL (C-20) and
STAT5 (C-17) from Santa Cruz and p62
DOK from Covance
Research Products (Grand Rapids, MI, USA). Immunoprecipitat-
ed lysates were separated on SDS-PAGE gels and transferred to
PVDF membranes as above and the membranes were incubated
with the following antibodies: anti-phosphotyrosine (4G10), anti-
GRB2 (3F2), Millipore Corporation, anti-ABL (2411), anti-CRKL
(C20), anti-STAT5 (C-17) and anti-p62
DOK (A3) from Santa Cruz
and anti-CBL from BD Biosciences (San Diego, CA, USA).
Generation of retrovirus
Bosc23 cells [39] were maintained in Dulbecco’s Modified
Eagles Medium (DMEM) supplemented with 10% FBS, 1 U/mL
penicillin, and 1 mg/mL streptomycin. For production of retrovi-
rus, Bosc23 cells were transiently transfected with MIG-WT,
MIG-Triple or control MIG vector retrovirus, using Fugene
(Roche). The viral supernatants were harvested after 48 hours
post-transfection. For titration of retroviral supernatants, 100,000
NIH3T3 cells were infected in 35 mm plates with graded amounts
of supernatant [44]. After 48 hours the cells were analyzed for
GFP expression by FACS using a BD FACSAria
TM (BD
Biosciences). Volumes of supernatant containing equal amounts
of infectious particles were used to infect primary hematopoietic
cells.
Analysis of phospho-STAT5 in primary cells
Bone marrow was harvested from non 5-fluorouracil treated
Balb/c mice, erythrocytes were lysed with HN4Cl/KHCO3
solution and the cells were incubated overnight at 37uCi n
DMEM supplemented with 10% FBS, 10% WEHI conditioned
media, 6 ng/mL murine IL-3, 10 ng/mL murine IL-6 and 50 ng/
mL murine SCF (PeproTech, Inc., Rocky Hill, NJ). The following
day fresh media, plus 1 mM HEPES, 2 ug/mL polybrene
(American BioAnalytical, Natick, MA) and matched retroviral
stock for the triple mutant, wild type or vector control was added,
and cells were subjected to two rounds of transduction and co-
sedimentation 24 hours apart, separated by incubation overnight
at 37uC[45]. After the second overnight incubation, GFP positive
cells were sorted and collected with a BD FACSAria
TM (BD
Biosciences, San Jose, CA) followed again by incubation overnight
in DMEM supplemented with 10% FBS, IL-3, IL-6 and SCF.
Cells were washed twice and starved for 4 hours in DMEM
without serum or cytokines. After starvation 5610
5 cells were fixed
with BD
TM Cytofix buffer (10 minutes on ice), permeabilized with
BD
TM Phosflow Perm Buffer III (30 minutes on ice), washed with
BD Pharmingen
TM Stain Buffer+FBS and stained with the Alexa
FluorH 647 mouse anti-Stat5 (pY694) antibody (30 minutes at
room temperature, in the dark), followed by analysis on a BD
FACSAria
TM. Remaining cells were lysed for western analysis of
pSTAT5 (Y694) (Cell Signaling) and BCR-ABL (c-ABL, Santa
Cruz), stripped and re-probed for STAT5 (Santa Cruz).
B-lymphoid transformation
To analyze the transformation of primary bone marrow B-
lymphoid progenitors, bone marrow from non 5-fluorouracil
treated mice was used [4]. Erythrocytes were lysed with HN4Cl/
KHCO3solution and the cells were subjected to a single round of
transduction and co-sedimentation with matched retroviral stock
for the triple mutant, wild type and vector control in DMEM
supplemented with 10% FBS. Cells were incubated overnight in
the presence of viral supernatant. The cells were then plated for in
vitro growth in Whitlock/Witte cultures in RPMI 1640 supple-
mented with 5% FBS, 200 mM L-glutamine, 50 mM 2-mercapto-
noethanol and penicillin/streptomycin as described [20,46]. Cells






3 cells/mL, along with 1610
6 non-
transduced bone marrow cells. Cells were cultured for three weeks
and fed twice weekly by the removal of 0.5 mL of supernatant and
addition of 0.5 mL of fresh media. Cultures were scored as positive
for transformation when the number of non-adherent cells
exceeded 10
6 per mL of culture medium.
Myeloid Colony Forming Assays
For myeloid progenitor colony formation bone marrow was
harvested from 6-10 week old female Balb/c mice. Bone marrow
was subjected to 24 hours prestimulation at 37uC in IMDM
(Invitrogen, Carlsbad, CA, USA) supplemented with 5% heat-
inactivated FBS, 5% WEHI conditioned media, 6 ng/mL murine
IL-3, 10 ng/mL murine IL-6 and 50 ng/mL murine SCF (Stem
Cell Technologies, Vancouver, BC, Canada) [45]. After 24 hours
of prestimulation, equal numbers of cells were transferred to 6-well
plates and exposed to matched viral supernatants in the presence
of 2 ug/mL polybrene in the same media as above. Cells were
then co-sedimented at 30uC for 90 mins at 2500 rpm [44] and
returned to the 37uC incubator overnight. After overnight
incubation, cells were washed twice in IMDM to remove cytokines
and plated in duplicate at 1610
5 cells in Methocult M3234
without cytokines or erythropoietin or in Methocult M3534
containing IL-3, IL-6 and SCF (Stem Cell Technologies). Cells
were incubated at 37uC, 5% CO2 for 7 days after which the
number of colonies were counted and are reported as a percentage
of the number of wild type colonies formed. Genomic DNA was
isolated from colonies using the Qiagen (Valencia, CA, USA)
micro DNA kit and used in PCR as described below.
Bone marrow transduction/transplantation
Murine bone marrow transduction and transplantation was
performed as previously described [2]. Briefly, bone marrow cells
were isolated from the tibias and femurs of 6-8 week old male
Balb/c donor mice 4–5 days after intravenous treatment with
300 mg/kg of 5-fluorouracil (Sigma-Aldrich, St. Louis, MO,
USA). Bone marrow cells (2610
6 cells) were infected with either
MIG-WT, MIG-triple mutant-BCR-ABL or control MIG retro-
viral supernatant matched by titering in NIH-3T3 cells as
described above, in DMEM (final concentration of viral
supernatant of 35%), containing 1 U/mL penicillin, 1 mg/mL
streptomycin, 2 mM L-glutamine, 15% FBS, 15% WEHI, 7 ng/
mL interleukin-3, 12 ng/mL interleukin-6, 56 ng/mL stem cell
factor, and 3 mg/mL polybrene, by two rounds of spinoculation
[44]. Following infection, the cells were washed extensively in
phosphate buffered saline (PBS) and 4610
5 cells were injected into
the retro-orbital vein of recipient mice that had been exposed to
two doses of 450 rad whole-body irradiation in a cesium irradiator
administered 4 hours apart. After transplant, recipients were
housed in microisolator cages supplied with water supplemented
with antibiotics (Augmentin, OHSU pharmacy). Mice were
monitored daily post transplant to look for signs of disease onset.
White blood counts (WBC) and three-part differential blood
counts were analyzed weekly using a Vet ABC blood analyzer
(Heska Inc., Fort Collins, CO, USA).
PCR amplification of GFP
Genomic DNA was isolated from myeloid colonies as described
above. RNA was isolated from frozen tissue sections of spleens
using the RNeasy isolation kit (Qiagen). cDNA was amplified
using the Superscript III kit (Invitrogen) and used in PCR to
amplify GFP from individual animals as described by Zhang, et al
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gene as described [47]Results were visualized on agarose gels.
Southern Blot
Proviral integration was assessed by Southern blotting. Ten ug
of genomic DNA from frozen spleen sections and bone marrow
isolated at harvest was digested with EcoR1 and Sal1, run out on
0.8% agarose gel, transferred to Hybond-N+ (GE Healthcare,
Piscataway, NJ, USA) and hybridized with a radioactive probe
from the IRES gene in MIG-R1. Results were visualized on a
Typhoon Imager (GE Healthcare).
Pathological examination of diseased mice
For survival analysis, mice were monitored with weekly blood
counts using a Vet ABC blood analyzer (Heska Inc.). Animals were
sacrificed by CO2 asphyxiation when the white blood cell count
exceeded 200/nl, if there was greater than 20% loss of body
weight, or if they appeared moribund (IACUC guidelines, Oregon
Health & Science University). For pathological analysis tissues
were harvested, weighed and analyzed histologically, when the
mice were sacrificed or when spontaneous death occurred.
Paraffin-embedded thin sections of liver and spleen were stained
with hematoxylin and eosin (H&E). Peripheral blood smears were
stained with Wright/Giemsa stain. White blood counts (WBC) and
three-part differential blood counts were analyzed from peripheral
blood using the Vet ABC blood analyzer.
Ethics Statement
All mice used in these experiments were housed and cared for in
the OHSU Animal Care Facility under the supervision of the
facility’s veterinary staff. OHSU is an AAALAC accredited
institution, meeting or exceeding all standards for animal care
and use. This study has been reviewed and approved by the
OHSU’s Institutional Animal Care and Use Committee (IACUC).
All procedures, such as injections and test bleeds, were performed
by experienced personnel according to guidelines established by
the IACUC, designed to ensure minimal discomfort and distress of
the animals.
Supporting Information
Figure S1 Growth curves of the triple mutant and BCR-ABL
clones. Independent clones of 32D cells expressing either BCR-
ABL wild type or triple mutant were isolated from soft agar
cultures and their ability to grow in the absence of IL-3 was
evaluated in cell proliferation assays. A representative cell
proliferation assay with two wild type and four triple mutant
clones is shown.
Found at: doi:10.1371/journal.pone.0007439.s001 (0.30 MB
DOC)
Table S1 Relative percentage of GFP positive cells in bone
marrow used for transplantation. Flow cytometric analysis of the
percentage of GFP positive bone marrow cells post infection with
the indicated retroviral supernatants used in the bone marrow
transplantation/transduction experiments.
Found at: doi:10.1371/journal.pone.0007439.s002 (0.03 MB
RTF)
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